疫苗前沿 | 延缓1型糖尿病疾病进展，创新免疫疗法进入FDA审评阶段

参考资料：

[1] Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals. Retrieved March 21, 2022, from https://www.prnewswire.com/news-releases/provention-bio-announces-fda-acceptance-of-the-biologics-license-application-bla--resubmission-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-in-at-risk-individuals-301506191.html

[2] Teplizumab Overview. Retrieved Aug 5, 2019, from https://www.creativebiolabs.net/teplizumab-overview.htm

来源：药明康德

END